Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer

被引：96

作者：

Freimund, Alison E. ^{[1
,2
]}

Beach, Jessica A. ^{[1
]}

Christie, Elizabeth L. ^{[1
,2
]}

Bowtell, David D. L. ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Res Div, 305 Grattan St, Melbourne, Vic 3000, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3010, Australia

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期

关键词：

Ovarian cancer; Primary resistance; Acquired resistance; Chemotherapy; Drug resistance mechanisms; HOMOLOGOUS RECOMBINATION; PARP INHIBITORS; PHASE-II; MULTIDRUG-RESISTANCE; GENE AMPLIFICATION; CELL CARCINOMA; POOR SURVIVAL; PLATINUM; CHEMOTHERAPY; EXPRESSION;

D O I：

10.1016/j.hoc.2018.07.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Resistance in ovarian cancer is driven by a range of mechanisms, some of which are therapy specific whereas others confer multidrug resistance. This review outlines our current understanding of the heterogeneous mechanisms of both primary and acquired drug resistance in high-grade serous ovarian cancer with a focus on the most common therapeutics, including platinum and taxanes. Current therapeutic strategies for overcoming resistance, including the use of non-P-glycoprotein substrate therapies, are outlined, with an emphasis on the importance of developing resistance biomarkers to guide future therapy approaches and improve patient outcomes.

引用

页码：983 / +

页数：15

共 80 条

[1]

Altaha R, 2004, INT J MOL MED, V14, P959

[2] FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway [J].

Asad, M. ;

Wong, M. K. ;

Tan, T. Z. ;

Choolani, M. ;

Low, J. ;

Mori, S. ;

Virshup, D. ;

Thiery, J. P. ;

Huang, R. Y-J .

CELL DEATH & DISEASE, 2014, 5 :e1346-e1346

[3] Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition [J].

Au-Yeung, George ;

Lang, Franziska ;

Azar, Walid J. ;

Mitchell, Chris ;

Jarman, Kate E. ;

Lackovic, Kurt ;

Aziz, Diar ;

Cullinane, Carleen ;

Pearson, Richard B. ;

Mileshkin, Linda ;

Rischin, Danny ;

Karst, Alison M. ;

Drapkin, Ronny ;

Etemadmoghadam, Dariush ;

Bowtell, David D. L. .

CLINICAL CANCER RESEARCH, 2017, 23 (07) :1862-1874

[4] Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling [J].

Bashashati, Ali ;

Ha, Gavin ;

Tone, Alicia ;

Ding, Jiarui ;

Prentice, Leah M. ;

Roth, Andrew ;

Rosner, Jamie ;

Shumansky, Karey ;

Kalloger, Steve ;

Senz, Janine ;

Yang, Winnie ;

McConechy, Melissa ;

Melnyk, Nataliya ;

Anglesio, Michael ;

Luk, Margaret T. Y. ;

Tse, Kane ;

Zeng, Thomas ;

Moore, Richard ;

Zhao, Yongjun ;

Marra, Marco A. ;

Gilks, Blake ;

Yip, Stephen ;

Huntsman, David G. ;

McAlpine, Jessica N. ;

Shah, Sohrab P. .

JOURNAL OF PATHOLOGY, 2013, 231 (01) :21-34

[5] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[6] PARP inhibitors: Clinical utility and possibilities of overcoming resistance [J].

Bitler, Benjamin G. ;

Watson, Zachary L. ;

Wheeler, Lindsay J. ;

Behbakht, Kian .

GYNECOLOGIC ONCOLOGY, 2017, 147 (03) :695-704

[7] RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].

BLACKLEDGE, G ;

LAWTON, F ;

REDMAN, C ;

KELLY, K .

BRITISH JOURNAL OF CANCER, 1989, 59 (04) :650-653

[8] 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers [J].

Bouwman, Peter ;

Aly, Amal ;

Escandell, Jose M. ;

Pieterse, Mark ;

Bartkova, Jirina ;

van der Gulden, Hanneke ;

Hiddingh, Sanne ;

Thanasoula, Maria ;

Kulkarni, Atul ;

Yang, Qifeng ;

Haffty, Bruce G. ;

Tommiska, Johanna ;

Blomqvist, Carl ;

Drapkin, Ronny ;

Adams, David J. ;

Nevanlinna, Heli ;

Bartek, Jiri ;

Tarsounas, Madalena ;

Ganesan, Shridar ;

Jonkers, Jos .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (06) :688-U56

[9] Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer [J].

Bowtell, David D. ;

Boehm, Steffen ;

Ahmed, Ahmed A. ;

Aspuria, Paul-Joseph ;

Bast, Robert C., Jr. ;

Beral, Valerie ;

Berek, Jonathan S. ;

Birrer, Michael J. ;

Blagden, Sarah ;

Bookman, Michael A. ;

Brenton, James D. ;

Chiappinelli, Katherine B. ;

Martins, Filipe Correia ;

Coukos, George ;

Drapkin, Ronny ;

Edmondson, Richard ;

Fotopoulou, Christina ;

Gabra, Hani ;

Galon, Jerome ;

Gourley, Charlie ;

Heong, Valerie ;

Huntsman, David G. ;

Iwanicki, Marcin ;

Karlan, Beth Y. ;

Kaye, Allyson ;

Lengyel, Ernst ;

Levine, Douglas A. ;

Lu, Karen H. ;

McNeish, Iain A. ;

Menon, Usha ;

Narod, Steven A. ;

Nelson, Brad H. ;

Nephew, Kenneth P. ;

Pharoah, Paul ;

Powell, Daniel J., Jr. ;

Ramos, Pilar ;

Romero, Iris L. ;

Scott, Clare L. ;

Sood, Anil K. ;

Stronach, Euan A. ;

Balkwill, Frances R. .

NATURE REVIEWS CANCER, 2015, 15 (11) :668-679

[10] Targeting DNA Repair in Cancer : Beyond PARP Inhibitors [J].

Brown, Jessica S. ;

O'Carrigan, Brent ;

Jackson, Stephen P. ;

Yap, Timothy A. .

CANCER DISCOVERY, 2017, 7 (01) :20-37

← 1 2 3 4 5 6 7 8 →